Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

I maintain my buy rating on Esperion Therapeutics, Inc.(NASDAQ: ESPR ) given its strong Q3 2024 financial performance, which is a testament to the success of its unique value proposition discussed in my previousI am an experienced financial analyst and a former writer for Fade The Market on Seeking Alpha, with a passion for numbers and a knack for unraveling complex financial data. Armed with a strong financial modeling and data analysis background, I thrive on providing accurate insights and recommendation ...